Enveric Biosciences Inc.
| NASDAQ: ENVB | Healthcare / Biotechnology / USA |
| 2.54 | -0.1600 | -5.93% | Vol 22.58K | 1Y Perf -42.80% |
| Oct 4th, 2023 14:12 DELAYED |
| BID | 2.33 | ASK | 2.54 | ||
| Open | 2.59 | Previous Close | 2.70 | ||
| Pre-Market | 2.78 | After-Market | - | ||
| 0.08 2.96% | - - |
| Target Price | 32.50 | Analyst Rating | — 0.00 | |
| Potential % | 1.18K | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★★★ 66.68 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | ★★★★+ 64.67 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Price Range Ratio 52W % | 21.83 | Earnings Rating | — | |
| Market Cap | 5.46M | Earnings Date | 13th Nov 2023 | |
| Alpha | -0.09 | Standard Deviation | 0.29 | |
| Beta | 1.21 |
Today's Price Range 2.262.71 | 52W Range 1.306.98 | 5 Year PE Ratio Range -6.40-0.6000 |
Summary:
Buy
| Technical Indicators: | Buy |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 16.88% | ||
| 1 Month | 27.06% | ||
| 3 Months | -19.40% | ||
| 6 Months | 66.67% | ||
| 1 Year | -42.80% | ||
| 3 Years | -48.47% | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -120.89 | |||
ROE last 12 Months | -149.42 | |||
ROA (5Y Avg) | -39.83 | |||
ROA last 12 Months | -115.85 | |||
ROC (5Y Avg) | -74.92 | |||
ROC last 12 Months | -132.92 | |||
Return on invested Capital Q | -11.56 | |||
Return on invested Capital Y | -107.91 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 0.00 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.25 | ||||
| -1.23 | ||||
| - | ||||
| -0.40 | ||||
| -16.33 | ||||
| 0.38 | ||||
| 10.99 | ||||
| -15 417 800.00 | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 8.20 | ||||
| 8.60 | ||||
| 0.00 | ||||
| 0.00 | ||||
| -5 695.50 | ||||
| Leverage Ratio | 1.30 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 238.70 | ||||
| 84.00 | ||||
| 84.00 | ||||
| -18.50 | ||||
| 41.77 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.00 | ||||
| 0.00 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2024 | - | -3.04 | - |
| Q04 2022 | - | -0.75 | - |
| Q03 2022 | - | -1.46 | - |
| Q02 2022 | - | -2.73 | - |
| Q01 2022 | - | -5.50 | - |
| Q04 2021 | - | -7.00 | - |
| Q01 2021 | - | -10.00 | - |
| Q03 2020 | - | -0.80 | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | 13th Nov 2023 |
| Estimated EPS Next Report | -1.93 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 22.58K |
| Shares Outstanding | 2.15K |
| Shares Float | 2.04M |
| Trades Count | 169 |
| Dollar Volume | 55.62K |
| Avg. Volume | 51.50K |
| Avg. Weekly Volume | 36.55K |
| Avg. Monthly Volume | 29.38K |
| Avg. Quarterly Volume | 88.55K |
Enveric Biosciences Inc. (NASDAQ: ENVB) stock closed at 2.7 per share at the end of the most recent trading day (a 20% change compared to the prior day closing price) with a volume of 53.70K shares and market capitalization of 5.45M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 3 people. Enveric Biosciences Inc. CEO is David I. Johnson.
The one-year performance of Enveric Biosciences Inc. stock is -42.8%, while year-to-date (YTD) performance is 29.81%. ENVB stock has a five-year performance of %. Its 52-week range is between 1.3 and 6.98, which gives ENVB stock a 52-week price range ratio of 21.83%
Enveric Biosciences Inc. currently has a PE ratio of 0.00, a price-to-book (PB) ratio of 0.25, a price-to-sale (PS) ratio of -1.23, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -115.85%, a ROC of -132.92% and a ROE of -149.42%. The company’s profit margin is 41.77%, its EBITDA margin is 84.00%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from Enveric Biosciences Inc., there were 0 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-1.93 for the next earnings report. Enveric Biosciences Inc.’s next earnings report date is 13th Nov 2023.
The consensus rating of Wall Street analysts for Enveric Biosciences Inc. is — (0), with a target price of $32.5, which is +1 179.53% compared to the current price. The earnings rating for Enveric Biosciences Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Enveric Biosciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Enveric Biosciences Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 26.91, ATR14 : 0.26, CCI20 : 187.51, Chaikin Money Flow : 0.05, MACD : 0.01, Money Flow Index : 68.59, ROC : 18.42, RSI : 61.15, STOCH (14,3) : 92.80, STOCH RSI : 1.00, UO : 53.88, Williams %R : -7.20), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Enveric Biosciences Inc. in the last 12-months were:
Enveric Biosciences Inc.
Enveric Biosciences Inc is a patient-centric biotechnology company focused on developing new-generation, naturally occurring chemical compounds, such as cannabinoids to improve the lives of those who are adversely affected by the side effects of cancer treatments. Its product in the pipeline includes Glioblastoma Multiforme (GBM); Radiation Dermatitis and Chemotherapy-Induced Peripheral Neuropathy (CIPN).
CEO: David I. Johnson
Telephone: +1 239 302-1707
Address: 4851 Tamiami Trail N, Naples 34103, FL, US
Number of employees: 3
